Steven Artandi, MD, PhD

1.8K posts

Steven Artandi, MD, PhD banner
Steven Artandi, MD, PhD

Steven Artandi, MD, PhD

@SCIDirector

Stanford University medical oncologist and cancer scientist, and Director of the Stanford Cancer Institute. Follows and retweets are not endorsements.

Stanford, CA Katılım Kasım 2018
1.6K Takip Edilen3.9K Takipçiler
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
Ronald Castellino, pioneer in oncologic radiology, dies at 88. Castellino founded the first #RadiationOncology division at Stanford , led the diagnostic radiology department, and made important contributions to research in imaging the lymphatic system.brnw.ch/21x2JP5
English
0
0
0
215
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Beth Beadle & others report that in p16+ #OropharyngealCancer, quality of life outcomes at 6 months were similar for accelerated radiation with cisplatin or cetuximab, with persistent issues in dry mouth, sticky saliva, and senses. brnw.ch/21x2JOy
Steven Artandi, MD, PhD tweet media
English
2
0
1
185
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Chris Garcia & others use catch-bond engineering to enhance weak TCRs, boosting TCR potency against prostate cancer antigens while maintaining specificity. This strategy could overcome immune tolerance and improve TCR-based #CancerImmunotherapy. brnw.ch/21x2D6I
Steven Artandi, MD, PhD tweet media
English
0
1
1
166
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Nathanael Gray & others report that TRAP-1, a mutant-specific small molecule, activates p53Y220C via a ternary complex, restoring tumor suppressor function and inducing senescence and apoptosis in cancer cells. brnw.ch/21x2B1m #DrugDiscovery
English
0
1
1
203
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
A multidisciplinary expert thoracic panel, including SCI members Joel Neal and Joseph Shrager, released 19 consensus recommendations on managing locally advanced #LungCancer, covering resectability, neoadjuvant, and adjuvant therapies. brnw.ch/21x2sDC
Steven Artandi, MD, PhD tweet media
English
0
0
0
152
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI Esther John & others found that adding polygenic risk scores (PRS) to mammographic density (MD) didn’t improve contralateral #BreastCancer (CBC) risk prediction. MD remains the main predictor for CBC risk. brnw.ch/21x2obk
English
0
1
0
158
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Marvin Langston & others found that renal cell carcinoma incidence >, particularly among Hispanic, Black, and low-nSES groups. While overall mortality <, these groups faced > death rates, highlighting #RCC health equity concerns. brnw.ch/21x2frh
Steven Artandi, MD, PhD tweet media
English
0
1
5
265
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
A @STS_CTsurgery panel, including SCI member Joe Shrager, developed 19 consensus recommendations on managing locally advanced #NSCLC, focusing on resectability, the role of neoadjuvant & adjuvant therapies, & multidisciplinary treatment approaches. brnw.ch/21x2bhI
Steven Artandi, MD, PhD tweet media
English
0
0
0
145
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member @sumitshahMD & others studied virtual cancer second opinions, finding over half of patients received new treatment recommendations, showing online expert review can improve care access and guide better treatment decisions. brnw.ch/21x1YHQ
Steven Artandi, MD, PhD tweet media
English
0
2
3
169
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Ami Bhatt & others uncover a recent expansion of mobile DNA (ISL3) driving rapid genome changes in E. faecium, even within patients. In cancer transplant patients, this may help fuel adaptable, hard-to-treat infections. #MicrobialEvolution brnw.ch/21x1Ufi
Steven Artandi, MD, PhD tweet media
English
0
0
4
221
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Xuejun Gu & others developed TLC-nnUNet, improving #BrainMetastasis detection by focusing on small lesions and reducing false positives. Shows better accuracy across lesion sizes & holds promise for clinical use in stereotactic radiosurgery. brnw.ch/21x1PSu
Steven Artandi, MD, PhD tweet media
English
0
0
1
229
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member @LivnatJerby & others show #CRISPR activation screens uncover RNA-based mechanisms that sensitize cancer cells to T cell killing and reveal gene interactions like Wnt that can restore targeted immune elimination. brnw.ch/21x1H0i
Steven Artandi, MD, PhD tweet media
English
0
4
19
1.5K
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member @RaviMajetiMD & others show DNMT3A R882 mutations drive #AML initiation but are dispensable for maintenance, as CRISPR correction didn’t affect engraftment—highlighting distinct roles in initiation vs persistence. brnw.ch/21x1yEJ
English
0
1
13
1.6K
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member Ami Bhatt& others report that post-transplant cyclophosphamide disrupts the gut microbiome more than standard GVHD prevention—yet improves outcomes, challenging the link between diversity and success. brnw.ch/21x1ujV
Steven Artandi, MD, PhD tweet media
English
0
0
2
298
Steven Artandi, MD, PhD
Steven Artandi, MD, PhD@SCIDirector·
SCI member @MullallyLab & others created a model to predict survival in patients with #TP53 mutations in myeloproliferative neoplasms. Key factors like bone marrow scarring, multiple TP53 mutations, and a higher risk score linked to shorter survival. brnw.ch/21x1q72
Steven Artandi, MD, PhD tweet media
English
0
1
2
489